Travis J Cohoon

发表

Toward precision health: applying artificial intelligence analytics to digital health biometric datasets.

Travis J Cohoon, Sanjeev P Bhavnani, S. Bhavnani, 2020, Personalized medicine.

Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit.

Travis J Cohoon, N. Hacohen, J. Mesirov, 2014, Cancer discovery.

The pivotal role of IKKα in the development of spontaneous lung squamous cell carcinomas.

Travis J Cohoon, Kwok-Kin Wong, G. Trinchieri, 2013, Cancer cell.

Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer

Travis J Cohoon, Kwok-Kin Wong, J. Qi, 2013, Clinical Cancer Research.

Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth.

Travis J Cohoon, J. Mesirov, P. Tamayo, 2014, The Journal of clinical investigation.

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models.

Travis J Cohoon, Erin M. Coffee, T. Shioda, 2013, Cancer cell.

D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice

Travis J Cohoon, K. Ligon, Kwok-Kin Wong, 2014, Genes & development.

Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer.

Travis J Cohoon, D. Hayes, D. Root, 2013, Cancer discovery.

Cancer Therapy : Preclinical Ef fi cacy of BET Bromodomain Inhibition in Kras-Mutant Non – Small Cell Lung Cancer

Junqi, Travis J Cohoon, Kwok-Kin Wong, 2013 .

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Travis J Cohoon, M. Meyerson, D. Hayes, 2013, Cancer discovery.

Abstract PR09: Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS-mutant cancer models

Travis J Cohoon, Erin M. Coffee, T. Shioda, 2013 .